STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2004 NEW YORK

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS. BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY. BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2 CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b} NONDUAL BENEFICIARIES, NEW YORK, 2004

			Number of Be	neficiaries				1	Number of Be	nefit Months		
Beneficiary						Other/						Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	3,109,338	35,195	422,618	987,343	1,663,459	723	26,041,145	328,669	4,592,552	7,578,435	13,536,447	5,042
Age												
5 and younger	652,028	6	20,981	0	631,041	0	5,221,063	39	207,056	0	5,013,968	0
6-14	649,807	0	55,010	0	594,797	0	5,853,786	0	600,828	0	5,252,958	0
15-20	377,562	0	37,514	0	340,003	45	3,215,492	0	406,722	0	2,808,494	276
21-44	883,019	0	121,131	756,571	4,940	377	7,001,137	0	1,325,528	5,651,583	21,721	2,305
45-64	413,156	0	182,189	230,661	6	300	3,920,808	0	1,991,967	1,926,345	47	2,449
65-74	21,106	16,326	4,668	111	0	1	201,909	151,932	49,458	507	0	12
75-84	11,062	10,186	876	0	0	0	104,553	95,905	8,648	0	0	0
85 and older	8,718	8,473	245	0	0	0	82,500	80,162	2,338	0	0	0
Unknown	92,880	204	4	0	92,672	0	439,897	631	7	0	439,259	0
Gender												
Female	1,739,646	23,263	214,401	671,307	829,952	723	14,735,249	219,688	2,354,112	5,333,408	6,822,999	5,042
Male	1,315,367	11,901	208,215	316,036	779,215	0	10,994,298	108,820	2,238,435	2,245,027	6,402,016	0
Unknown	54,325	31	2	0	54,292	0	311,598	161	5	0	311,432	0
Race												
White	970,791	10,065	131,889	321,733	506,553	551	8,235,692	92,629	1,426,307	2,465,871	4,247,026	3,859
African American	775,629	5,994	102,142	289,717	377,706	70	6,342,160	54,301	1,100,595	2,194,207	2,992,591	466
Other/unknown	1,362,918	19,136	188,587	375,893	779,200	102	11,463,293	181,739	2,065,650	2,918,357	6,296,830	717
Use of Nursing Facilities ^c												
Entire year	8,669	1,628	6,878	130	33	0	95,700	16,770	77,380	1,219	331	0
Part year	9,088	917	7,191	885	95	0	94,006	8,877	75,901	8,287	941	0
None	3,091,581	32,650	408,549	986,328	1,663,331	723	25,851,439	303,022	4,439,271	7,568,929	13,535,175	5,042
Maintenance Assistance Status												
Cash	1,399,365	9,165	365,770	286,362	738,068	0	12,819,455	86,400	4,053,817	2,365,331	6,313,907	0
Medically needy	529,163	21,838	54,292	166,159	286,874	0	4,033,506	203,318	515,790	1,199,739	2,114,659	0
Poverty-related	538,881	6	1	828	537,323	723	4,190,198	44	12	5,537	4,179,563	5,042
Other/unknown	641,929	4,186	2,555	533,994	101,194	0	4,997,986	38,907	22,933	4,007,828	928,318	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	1,219,934	30,789	335,600	336,859	515,973	713	10,613,900	288,978	3,717,520	2,552,588	4,049,824	4,990
FFS part year, with Rx claims	460,461	969	19,730	189,824	249,930	8	1,704,326	4,857	102,649	701,409	895,363	48
FFS part year, no Rx claims	309,687	582	3,276	104,369	201,458	2	1,023,940	1,934	13,903	342,628	665,471	4
MC all year, with FFS Rx claims	1,119,256	2,855	64,012	356,291	696,098	0	12,698,979	32,900	758,480	3,981,810	7,925,789	0

Table ND2 Nondual Beneficiaries

- a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{9, b} NONDUAL BENEFICIARIES, NEW YORK, 2004

Beneficiary	Percentage with at	Mean Number			Mean \$, All Medicaid	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics	Least One Rx	of Rx	Mean Rx \$	\$ per Rx	FFS \$ ^c	FFS \$ ^d	Beneficiaries
All	68.2 %	9.5	\$845	\$89	\$4,766	17.7 %	3,109,338
Age							
5 and younger	69.0	3.7	208	57	2,025	10.3	652,028
6-14	69.2	4.5	361	80	2,073	17.4	649,807
15-20	61.8	4.3	351	81	3,113	11.3	377,562
21-44	70.3	10.2	986	97	6,326	15.6	883,019
45-64	82.5	31.3	2,906	93	11,872	24.5	413,156
65-74	68.2	23.1	1,683	73	11,515	14.6	21,106
75-84	50.6	17.4	1,213	70	11,940	10.2	11,062
85 and older	18.0	5.8	404	70	9,375	4.3	8,718
Unknown	4.2	0.1	9	74	323	2.8	92,880
Basis of Eligibility ^e							
Aged	51.8	16.4	1,158	71	10,349	11.2	35,195
Disabled	80.8	32.3	3,447	107	21,286	16.2	422,618
Adults	71.3	9.8	796	81	3,298	24.1	987,343
Children	63.5	3.4	207	61	1,323	15.6	1,663,459
Unknown	62.0	9.1	1,574	172	5,886	26.7	723
Gender							
Female	71.5	10.4	836	80	4,142	20.2	1,739,646
Male	66.3	8.7	891	102	5,766	15.5	1,315,367
Unknown	6.8	0.2	15	75	544	2.8	54,325
Race							
White	69.9	10.3	856	83	4,922	17.4	970,791
African American	67.4	8.9	868	97	5,016	17.3	775,629
Other/unknown	67.5	9.3	824	89	4,513	18.3	1,362,918
Use of Nursing							
Facilities ^f							
Entire year	54.8	22.5	3,720	165	92,611	4.0	8,669
Part year	81.3	38.2	5,626	147	86,755	6.5	9,088
None	68.2	9.4	823	88	4,279	19.2	3,091,581
Maintenance Assistance Status							
Cash	74.1	13.0	1,211	93	6,739	18.0	1,399,365
Medically needy	62.1	6.5	494	76	4,187	11.8	529,163
Poverty related	65.5	3.3	192	58	1,033	18.6	538,881
Other/unknown	62.7	9.7	886	92	4,079	21.7	641,929

Table ND3 Nondual Beneficiaries

- a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving fost care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, NEW YORK, 2004

					N	umber of Rx, Per	centage with:			_	Numb	er
Beneficiary Characteristics	Mean Number of Rx	A Mean Rx \$	Rx \$ as a centage of Il Medicaid FFS \$ ^c	None	0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than	Mean \$, All Medicaid FFS \$ ^d	Beneficiaries	Benefit Months
All	1.1	\$101	17.7 %	31.8 %	48.2 %	6.9 %	7.9 %	3.7 %	1.4 %	\$569	3,109,338	26,041,145
Age												
5 and younger	0.5	26	10.3	31.0	59.5	5.0	3.3	0.9	0.4	253	652,028	5,221,063
6-14	0.5	40	17.4	30.8	59.7	5.0	3.5	0.8	0.3	230	649,807	5,853,786
15-20	0.5	41	11.3	38.2	52.0	4.8	3.7	1.0	0.3	366	377,562	3,215,492
21-44	1.3	124	15.6	29.7	46.1	9.0	9.7	3.9	1.6	798	883,019	7,001,137
45-64	3.3	306	24.5	17.5	26.7	11.8	23.4	15.0	5.6	1,251	413,156	3,920,808
65-74	2.4	176	14.6	31.8	22.7	12.0	21.4	9.9	2.2	1,204	21,106	201,909
75-84	1.8	128	10.2	49.4	16.7	8.4	16.6	7.5	1.4	1,263	11,062	104,553
85 and older	0.6	43	4.3	82.0	7.3	2.9	4.5	2.9	0.4	991	8,718	82,500
Unknown	0.0	2	2.8	95.8	3.7	0.3	0.1	0.0	0.0	68	92,880	439,897
Basis of Eligibility ^e												
Aged	1.8	124	11.2	48.2	18.5	9.1	15.9	6.9	1.4	1,108	35,195	328,669
Disabled	3.0	317	16.2	19.2	28.6	11.1	22.1	14.5	4.6	1,959	422,618	4,592,552
Adults	1.3	104	24.1	28.7	45.6	9.5	10.3	3.9	1.9	430	987,343	7,578,435
Children	0.4	25	15.6	36.5	55.4	4.3	2.8	0.7	0.3	163	1,663,459	13,536,447
Unknown	1.3	226	26.7	38.0	37.3	10.9	10.2	3.3	0.1	844	723	5,042
Gender												
Female	1.2	99	20.2	28.5	49.9	7.3	8.6	4.1	1.6	489	1,739,646	14,735,249
Male	1.0	107	15.5	33.7	47.8	6.6	7.5	3.3	1.2	690	1,315,367	10,994,298
Unknown	0.0	3	2.8	93.2	6.1	0.5	0.2	0.0	0.0	95	54,325	311,598
Race												
White	1.2	101	17.4	30.1	48.3	7.3	8.5	4.1	1.7	580	970,791	8,235,692
African American	1.1	106	17.3	32.6	48.1	6.8	7.7	3.5	1.3	614	775,629	6,342,160
Other/unknown	1.1	98	18.3	32.5	48.3	6.8	7.7	3.5	1.2	537	1,362,918	11,463,293
Use of Nursing Facilities ^f												
Entire year	2.0	337	4.0	45.2	22.1	8.9	12.3	7.9	3.6	8,389	8,669	95,700
Part year	3.7	544	6.5	18.7	22.0	11.3	23.2	18.4	6.4	8,387	9,088	94,006
None	1.1	98	19.2	31.8	48.4	6.9	7.9	3.6	1.4	512	3,091,581	25,851,439
Maintenance Assistance Status												
Cash	1.4	132	18.0	25.9	50.5	7.3	9.5	5.1	1.7	736	1,399,365	12,819,455
Medically needy	0.9	65	11.8	37.9	45.8	6.6	6.4	2.3	1.0	549	529,163	4,033,506
Poverty related	0.4	25	18.6	34.5	56.7	4.6	3.0	0.8	0.4	133	538,881	4,190,198
Other/unknown	1.2	114	21.7	37.3	38.3	8.3	10.1	4.0	2.0	524	641,929	4,997,986

Table ND4 Nondual Beneficiaries

- a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{6, b, c}

NONDUAL BENEFICIARIES, NEW YORK, 2004

Beneficiary		All Rx		Patented Br	and-Name	Drugs	Off-Patent B	rand-Name	Drugs	Gen	eric Drugs	
<u>-</u>	Number			Number			Number			Number		
Beneficiary Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	1.1	\$101	\$89	0.5	\$80	\$149	0.1	\$6	\$84	0.5	\$15	\$29
Age												
5 and younger	0.5	26	57	0.2	20	130	0.0	1	42	0.3	5	17
6-14	0.5	40	80	0.2	33	133	0.0	2	67	0.2	6	25
15-20	0.5	41	81	0.2	32	138	0.0	2	76	0.3	8	30
21-44	1.3	124	97	0.6	98	167	0.1	8	92	0.6	18	30
45-64	3.3	306	93	1.6	242	147	0.2	18	93	1.4	46	32
65-74	2.4	176	73	1.3	141	108	0.1	8	61	1.0	27	28
75-84	1.8	128	70	1.0	103	103	0.1	5	52	0.7	20	28
85 and older	0.6	43	70	0.3	34	109	0.0	2	54	0.3	7	26
Unknown	0.0	2	74	0.0	2	225	0.0	0	37	0.0	0	16
Basis of Eligibility ^d												
Aged	1.8	124	71	1.0	100	104	0.1	5	56	0.7	19	27
Disabled	3.0	317	107	1.5	254	172	0.2	19	104	1.3	43	34
Adults	1.3	104	81	0.6	81	136	0.1	6	77	0.6	17	28
Children	0.4	25	61	0.2	19	114	0.0	1	50	0.2	5	22
Unknown	1.3	226	172	0.5	181	339	0.1	3	42	0.7	42	60
Gender												
Female	1.2	99	80	0.6	76	135	0.1	6	76	0.6	17	28
Male	1.0	107	102	0.5	87	170	0.1	6	100	0.5	14	30
Unknown	0.0	3	75	0.0	2	231	0.0	0	37	0.0	0	15
Race												
White	1.2	101	83	0.6	77	136	0.1	6	86	0.6	17	30
African American	1.1	106	97	0.5	86	170	0.1	6	88	0.5	14	28
Other/unknown	1.1	98	89	0.5	78	148	0.1	5	82	0.5	14	29
Use of Nursing Facilities ^e												
Entire year	2.0	337	165	1.4	304	217	0.1	9	119	0.5	23	41
Part year	3.7	544	147	2.0	467	236	0.2	27	120	1.5	49	33
None	1.1	98	88	0.5	78	147	0.1	6	84	0.5	15	29
Maintenance Assistance												
Status Cash	4 4	132	02	0.7	404	450	0.4	0	04	0.7	20	20
	1.4	65	93	0.7	104	156 128	0.1	8	91 65	0.7	20	30
Medically needy	0.9		76	0.4	50 10		0.1	4	65 40	0.4	11	28
Poverty related	0.4	25	58	0.2	19	108	0.0	1	49	0.2	5	21
Other/unknown	1.2	114	92	0.6	92	149	0.1	6	87	0.6	16	29

Table ND5 Nondual Beneficiaries

- a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In New York, 0.6 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

NONDUAL BENEFICIARIES, NEW YORK, 2004

			per Be		\$ per E	Benefit M Use		nong		\$ pe	r Rx			_		Users ^e	
Therapeutic Category	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.1	\$44	\$38	\$2	\$4	\$146	\$269	\$123	\$27	3,836,460	\$558,592,104	1,283,352	41.3 %	12,636,968
Biologicals	0.4	0.4	0.0	0.0	498	391	4	103	1216	1,116	307	2,205	39,251	47,742,474	10,491	0.3	95,924
Antineoplastic Agents	0.6	0.2	0.0	0.4	185	133	11	42	333	770	342	118	88,931	29,619,688	15,432	0.5	159,954
Endocrine/Metabolic Drugs	0.5	0.2	0.1	0.2	34	24	3	7	65	114	40	30	2,758,291	177,980,268	529,750	17.0	5,224,549
Cardiovascular Agents	1.2	0.6	0.1	0.6	61	46	2	13	49	75	43	22	4,509,940	222,526,403	353,843	11.4	3,634,476
Respiratory Agents	0.5	0.3	0.0	0.2	33	29	0	4	66	95	60	22	3,423,738	225,507,906	667,727	21.5	6,752,387
Gastrointestinal Agents	0.5	0.3	0.0	0.2	49	40	1	7	108	146	73	46	1,592,767	171,432,754	339,821	10.9	3,482,590
Genitourinary Agents	0.2	0.1	0.0	0.1	14	10	2	1	57	72	42	27	381,424	21,607,529	164,653	5.3	1,595,163
CNS Drugs	1.0	0.6	0.1	0.4	116	96	5	14	120	173	107	39	4,263,113	509,644,246	425,988	13.7	4,392,193
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.6	0.5	0.0	0.1	59	53	0	5	103	113	106	53	393,184	40,492,609	65,548	2.1	686,399
Neurological Agents	0.3	0.2	0.0	0.1	78	66	2	11	293	377	105	139	77,029	22,541,546	27,769	0.9	289,544
Analgesics and Anesthetics	0.4	0.1	0.0	0.2	22	16	1	5	62	144	375	20	2,973,592	183,163,703	836,020	26.9	8,313,207
Neuromuscular Agents	0.6	0.2	0.1	0.3	57	34	15	8	90	146	119	29	1,491,140	134,304,255	225,839	7.3	2,348,573
Nutritional Products	0.2	0.0	0.0	0.2	5	1	0	4	19	28	30	18	372,082	7,180,310	163,704	5.3	1,511,679
Hematological Agents	0.5	0.2	0.1	0.3	116	108	3	5	221	590	47	17	457,593	101,096,336	86,020	2.8	872,749
Topical Products	0.3	0.1	0.0	0.2	16	10	1	5	55	91	60	31	2,727,936	148,998,086	915,644	29.4	9,157,526
Miscellaneous Products	0.5	0.2	0.1	0.2	145	101	26	17	273	459	442	69	73,621	20,110,438	14,247	0.5	139,136
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	9	0	0	0	38	0	0	0	142,018	5,432,152	55,129	1.8	583,805
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	29,602,110	2,627,972,807	n.a.	n.a.	n.a.

- a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In New York, 0.6 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.7

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{9, b, c}

NONDUAL BENEFICIARIES, NEW YORK, 2004

			Users		Ar	mong Users	
Top 10 Drug Groups	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	Rx \$ per Rx	\$ per Benefit Month
ANTIVIRAL	\$422,220,697	138,030	4.4 %	1,473,204	0.6	\$467	\$287
ANTIPSYCHOTICS	318,680,166	214,185	6.9	2,304,486	0.6	227	138
ANTIASTHMATIC	173,761,272	794,582	25.6	8,116,660	0.3	67	21
ANTIDEPRESSANTS	143,063,245	362,978	11.7	3,741,785	0.5	75	38
ULCER DRUGS	139,243,206	321,751	10.3	3,319,151	0.4	112	42
ANTICONVULSANT	118,832,432	161,901	5.2	1,726,043	0.6	112	69
DERMATOLOGICAL	114,413,205	1,131,102	36.4	11,528,745	0.2	54	10
ANALGESICS - ANTI-INFLAMMATORY	92,331,586	790,800	25.4	8,014,241	0.2	53	12
ANTIDIABETIC	90,473,800	198,057	6.4	2,058,665	0.6	69	44
ANTIHYPERLIPIDEMIC	88,781,742	163,089	5.2	1,733,715	0.5	94	51
Total	1,701,801,351	4,276,475		44,016,695	n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.7A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED

AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{8, b, c}

NONDUAL BENEFICIARIES, NEW YORK, 2004

	All Top 10 D	rug Groups		AN ⁻	TIVIRAL				ANTIPS	SYCHOTICS		
		_		Users	Number of Benefit Months	of Rx	Mean		Users	Number of Benefit Months	of Rx	Mean
Beneficiary			Number of	as % of All	Among	per Benefit	Rx \$ per Benefit	Number of	as % of All	Amona	Benefit	Rx \$ per Benefit
Characteristics	Number of Rx	Rx\$	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
All	15,190,572	\$1,701,801,351	138,030	4.4 %	1,473,204	0.6	\$287	214,185	6.9 %	2,304,486	0.6	\$138
Female	9,031,686	920,909,853	69,499	4.0	741,641	0.5	241	107,556	6.3	1,163,185	0.6	123
Disabled	4,530,930	537,679,221	30,671	14.3	352,044	0.6	300	68,422	31.9	781,756	0.6	140
Disableu	34,852	2,763,749	146	1.8	1,611	0.6	146	70	0.9	761	0.4	75
5 and younger	120,309	15,391,622	1,155	6.4	13,370	0.8	342	2,853	15.7	32,207	0.5	108
6-14	102,217	12,983,146	896	6.3	10,262	0.5	261	3,055	21.5	34,136	0.5	110
15-20	1,182,982	161,750,690	13,106	21.1	149,918	0.6	284	26,482	42.7	300,489	0.6	141
21-44	3,040,640	339,926,507	15,284	14.1	175,887	0.7	314	35.451	32.7	408,264	0.7	145
45-64	46,027	4,503,236	78	2.7	924	0.5	238	483	17.0	5,586	0.8	150
65-74	3,615	338.528	6	1.1	72	0.5	174	27	4.8	311	0.6	142
75-84	288	21,743	0	0.0	0	0.0	0	1	0.5	2	2.0	415
85 and older	4,500,670	383,227,262	38,828	2.6	389,597	0.4	189	39,134	2.6	381,429	0.4	87
Other Eligibles	489,738	21,375,429	1,376	0.4	13,638	0.4	33	191	0.1	1,980	0.4	54
5 and younger	537,130	33,804,352	1,886	0.4	19,989	0.4	135	4,207	1.4	44,471	0.5	91
6-14	326,890	23,017,229	3,364	1.6	33,059	0.4	85	4,207 4,425	2.2	44,924	0.5	73
15-20	•	167,145,289	24,389	4.5	241,019	0.3	185	4,425 21,128	3.9	199,212	0.4	73 84
21-44	1,726,464		•							,		
45-64	1,262,119	123,986,496	7,591	5.8	79,457	0.6	284	8,067	6.2	78,688	0.5	98
65-74	97,673	8,587,786	171	1.7	1,872	0.3	141	414	4.1	4,638	0.5	112
75-84	48,070	4,162,552	41	0.6	457	0.2	80	397	6.1	4,307	0.6	87
85 and older	12,586	1,148,129	10	0.2	106	0.1	24	305	4.7	3,209	0.6	81
Male	6,153,087	780,695,158	68,493	5.3	731,279	0.7	333	106,626	8.2	1,141,287	0.6	154
Disabled	2,972,746	452,119,092	34,726	16.7	392,338	0.8	360	67,463	32.4	767,941	0.7	172
Disabled	57,954	4,460,980	144	1.1	1,589	0.6	128	283	2.2	3,078	0.4	74
5 and younger	242,192	30,267,597	1,285	3.5	14,758	0.8	326	9,366	25.4	105,364	0.6	119
6-14	151,122	20,889,165	764	3.3	8,812	0.6	307	5,890	25.3	67,097	0.6	137
15-20	889,373	152,714,209	11,936	20.2	133,173	0.7	334	27,425	46.4	311,211	0.7	188
21-44	1,610,141	241,424,750	20,525	27.8	233,251	0.8	381	24,185	32.8	277,590	0.7	185
45-64	20,430	2,216,253	71	3.9	743	0.8	292	295	16.2	3,386	0.8	174
65-74	1,403	132,000	1	0.3	12	0.1	2	15	4.8	173	0.8	175
75-84	131	14,138	0	0.0	0	0.0	0	4	7.0	42	0.6	123
85 and older Other Eligibles	3,180,296	328,574,814	33,767	3.1	338,941	0.6	301	39,163	3.6	373,346	0.5	117
Other Eligibles	588,910	28,739,096	1,494	0.5	14,702	0.2	25	481	0.1	4,838	0.4	71
5 and younger	622,247	44,372,413	1,459	0.5	15,140	0.5	154	9,347	3.1	98,503	0.4	104
6-14	237,300	20,145,997	1,459	0.5	12,825	0.3	135	9,347 4,833	3.6	49,449	0.6	104
15-20	824,642	119,203,081	17,651	8.1	173,699	0.5	305	4,633 16,813	3.6 7.7	147,168	0.5	107
21-44	824,642 829,614	108,952,245	11,726	8.1 11.7	120,736	0.6	305 367	7,070	7.7 7.1	66,695	0.5	133
45-64	· · · · · · · · · · · · · · · · · · ·		•					,		•		
65-74	50,222	4,691,523	151	2.4	1,560	0.6	224	310	5.0	3,386	0.6	125
75-84	22,252	2,013,383	21	0.6	234	0.1	28	212	5.8	2,299	0.6	124
85 and older	5,109	457,076	5	0.2	45	0.2	11	97	4.8	1,008	0.7	106
Unknown	5,930	200,962	38	0.0	284	0.2	58	3	0.0	14	0.5	33

Table ND7A Nondual Beneficiaries

- a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7A Nondual Beneficiaries

TABLE ND.7B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,

BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

NONDUAL BENEFICIARIES, NEW YORK, 2004

		ANTIA	STHMATIC				ANTIDE	PRESSANTS				ULCE	R DRUGS		
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per
All	794,582	25.6 %	8,116,660	0.3	\$21	362,978	11.7 %	3,741,785	0.5	\$38	321,751	10.3 %	3,319,151	0.4	\$42
Female	440,605	25.6	4,544,121	0.3	22	242,326	14.1	2,522,590	0.5	38	210,521	12.2	2,199,147	0.4	42
Disabled	121,470	56.7	1,391,269	0.4	32	112,832	52.6	1,287,889	0.6	45	81,112	37.8	928,059	0.5	53
	4,619	57.3	50,421	0.3	27	27	0.3	304	0.3	10	984	12.2	10,528	0.4	32
5 and younger	8,156	45.0	94,109	0.4	26	1,291	7.1	14,500	0.5	32	1,205	6.6	14,026	0.4	39
6-14	4,478	31.5	51,185	0.3	23	2,697	19.0	30,344	0.5	36	1,388	9.8	15,875	0.3	31
15-20	30,693	49.5	349,205	0.4	27	37,025	59.7	417,819	0.5	43	19,785	31.9	224,814	0.4	47
21-44	72,561	67.0	835,440	0.5	35	71,023	65.6	816,056	0.6	46	56,612	52.3	649,893	0.5	57
45-64	897	31.5	10,174	0.4	30	716	25.2	8,301	0.5	37	1,026	36.1	11,731	0.5	54
65-74	65	11.5	730	0.5	35	42	7.4	465	0.5	33	98	17.4	1,065	0.5	55
75-84	1	0.5	5	1.8	40	11	5.9	100	0.4	43	14	7.4	127	0.4	35
85 and older Other Eligibles	319,117	21.2	3,152,768	0.3	18	129,494	8.6	1,234,701	0.4	32	129,407	8.6	1,271,080	0.3	33
	79,870	25.9	762,690	0.2	14	83	0.0	812	0.3	15	6,380	2.1	56,162	0.2	12
5 and younger	79,824	27.0	829,174	0.2	16	4,046	1.4	41,643	0.4	27	6,644	2.2	70,606	0.2	12
6-14	30,372	14.9	307,649	0.2	14	9,943	4.9	97,173	0.4	25	8,491	4.2	84,361	0.2	16
15-20	88,408	16.2	847,812	0.3	20	79,369	14.6	742,854	0.4	31	62,754	11.5	605,125	0.3	31
21-44	37,973	29.0	376,472	0.4	28	33,987	25.9	329,419	0.5	35	39,760	30.3	396,722	0.4	45
45-64	1,569	15.4	16,865	0.4	25	1,261	12.3	13,874	0.4	27	3,351	32.8	36,051	0.4	43
65-74	856	13.1	9,376	0.4	30	622	9.5	6,996	0.5	31	1,584	24.2	17,249	0.4	45
75-84	245	3.8	2,730	0.4	31	183	2.8	1,930	0.5	30	443	6.9	4,804	0.5	53
85 and older Male	353,076	27.3	3,566,544	0.3	21	120.642	9.3	1,219,096	0.5	38	111,053	8.6	1,118,805	0.4	43
	70,437	33.8	798,584	0.3	29	55,960	26.9	631,450	0.6	43	42,109	20.2	474,272	0.4	53
Disabled	8,388	64.9	91,911	0.4	29	92	0.7	1,048	0.8	16	1,311	10.1	14,080	0.3	31
5 and younger	17,723	48.1	203,428	0.3	24	3,141	8.5	35,384	0.5	34	1,734	4.7	20,038	0.4	39
6-14	6,192	26.6	71,665	0.3	24	3,141	13.9	36,914	0.5	40	1,483	6.4	17,007	0.4	38
15-20	11,851	20.0	134,085	0.3	26	19,648	33.2	219,758	0.6	46	11,077	18.7	124,386	0.4	51
21-44	25,899	35.1	293,144	0.4	36	29,507	40.0	334,581	0.6	43	26,036	35.3	293,482	0.4	57
45-64	25,699 351	19.2	3,982	0.5	34	29,307	16.7	3,538	0.5	38	429	23.5	4,848	0.5	56
65-74	30	9.6	333	0.3	27	20	6.4	217	0.6	38	35	11.2	385	0.3	51
75-84	3	5.3	36	0.4	3	1	1.8	10	0.0	8	4	7.0	46	0.5	54
85 and older Other Eligibles	282,635	26.0	2,767,934	0.1	18	64,680	5.9	587,638	0.1	33	68,942	6.3	644,527	0.3	35
Other Eligibles	109,998	34.1	1,043,228	0.3	16	146	0.0	1,382	0.3	12	7,932	2.5	69,527	0.3	
5 and younger	105,351	35.2	1,045,220	0.2	18	5,364	1.8	55,199	0.5	30	5,846	2.0	61,851	0.2	
6-14	22,965	16.9	235,478	0.3	16	5,062	3.7	49,872	0.4	31	4,346	3.2	43,485	0.2	
15-20	25,361	11.6	233,476	0.3	23	33,716	15.5	289,583	0.4	33	25,850	11.9	229,433	0.2	40
21-44	17,180	17.2	162,422	0.4	23 29	19,469	19.5	181,403	0.4	35 35	22,606	22.7	215,130	0.3	46
45-64	1,032	16.6	11,047	0.4	32	601	9.7	6,621	0.3	30	1,513	24.3	15,966	0.4	44
65-74	611	16.8	6,543	0.4	34	254	7.0	2,806	0.4	31	689	18.9	7,414	0.4	48
75-84	137	6.8	1,465	0.4	24	68	3.4	772	0.4	31	160	8.0	1,721	0.4	55
85 and older					4 -7								•		
Unknown	923	1.0	6,105	0.2	11	12	0.0	107	0.3	22	181	0.2	1,213	0.2	10

Table ND7B

- a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7B Nondual Beneficiaries

TABLE ND.7C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,
BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}
NONDUAL BENEFICIARIES, NEW YORK, 2004

		ANTICO	NVULSANT				DERMA	TOLOGICAL			ANAL	GESICS - A	NTI-INFLAMI	MATORY	
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	161,901	5.2 %	1,726,043	0.6	\$69	1,131,102	36.4 %	11,528,745	0.2	\$10	790,800	25.4 %	8,014,241	0.2	\$12
Female	93,530	5.4	1,003,002	0.6	66	663,447	38.6	6,811,000	0.2	10	508,334	29.5	5,178,722	0.2	13
Disabled	56,460	26.3	644,739	0.7	75	140,679	65.6	1,630,597	0.2	14	115,999	54.1	1,332,243	0.3	26
5 and younger	582	7.2	6,394	0.6	69	3,648	45.3	40,216	0.2	6	1,468	18.2	16,149	0.2	
6-14	2,684	14.8	30,801	0.7	93	7,721	42.6	89,354	0.2	7	3,318	18.3	38,297	0.2	
15-20	2,416	17.0	27,640	0.7	97	5,891	41.4	68,450	0.2	9	3,401	23.9	39,172	0.2	
21-44	20,357	32.8	230,904	0.7	86	36,576	59.0	422,819	0.2	12	31,454	50.7	358,929	0.3	17
45-64	30,059	27.7	344,823	0.6	64	85,313	78.7	991,961	0.2	15	75,018	69.2	864,176	0.3	32
65-74	336	11.8	3,896	0.6	49	1,408	49.5	16,442	0.2	15	1,228	43.2	14,232	0.3	32
75-84	20	3.5	219	0.4	26	103	18.3	1,152	0.2	13	105	18.6	1,211	0.3	31
85 and older	6	3.2	62	0.6	26	19	10.1	203	0.2	5	7	3.7	77	0.4	29
85 and older Other Eligibles	37,069	2.5	358,258	0.5	49	522,748	34.7	5,180,312	0.2	9	392,325	26.0	3,846,430	0.2	_
5 and younger	558	0.2	5,432	0.5	50	146,647	47.6	1,361,772	0.2	6	52,021	16.9	514,661	0.2	
6-14	2,131 2,610	0.7 1.3	21,781 25,768	0.6 0.5	62 62	110,676 58,780	37.5 28.8	1,168,412	0.1 0.2	7 9	53,395 40,978	18.1 20.1	567,330 405,470	0.1 0.2	2
15-20	20,329	3.7	191,681	0.5	50	141,845	26.0 26.1	602,453 1,371,917	0.2	11	169,912	31.2	1,592,225	0.2	
21-44	10,405	3.7 7.9	102,232	0.4	43	57,633	43.9	595,392	0.2	14	69,645	51.2 53.1	697,146	0.2	20
45-64	606	7.9 5.9	6.619	0.3	33	4.342	42.5	48,277	0.2	16	4,286	41.9	46.445	0.3	27
65-74	344	5.3	3,817	0.4	30	2,197	33.6	25,054	0.2	16	1,752	26.8	19,446	0.3	28
75-84	86	1.3	928	0.5	35	628	9.7	7,035	0.2	17	336	5.2	3,707	0.3	30
85 and older	00	1.5	320	0.5	33	020	5.1	7,000	0.2	17	330	5.2	3,707	0.0	30
Male	68,364	5.3	723,020	0.6	73	465,068	35.9	4,699,695	0.2	10	282,014	21.8	2,832,791	0.2	9
Disabled	41,820	20.1	475,998	0.7	84	92,492	44.4	1,063,611	0.2	13	59,599	28.6	676,775	0.3	18
E and vous sar	867	6.7	9,628	0.6	75	5,718	44.2	62,560	0.2	6	2,681	20.7	29,477	0.2	
5 and younger 6-14	4,723	12.8	53,933	0.7	84	12,955	35.1	149,650	0.2	7	5,819	15.8	67,359	0.2	
15-20	3,576	15.4	41,001	0.7	99	7,741	33.2	90,169	0.2	10	3,548	15.2	41,095	0.1	4
21-44	16,059	27.2	182,396	0.8	97	24,301	41.1	280,637	0.2	14	15,543	26.3	175,835	0.2	
45-64	16,402	22.2	186,808	0.7	70	41,071	55.6	472,290	0.3	17	31,521	42.7	357,338	0.3	26
65-74	177	9.7	2,062	0.7	53	650	35.6	7,663	0.2	16	438	24.0	5,114	0.3	25
75-84	13	4.2	138	0.6	76	53	17.0	608	0.2	12	46	14.7	523	0.3	21
	3	5.3	32	0.3	29	3	5.3	34	0.1	4	3	5.3	34	0.4	41
85 and older Other Eligibles	26,544	2.4	247,022	0.5	52	372,553	34.3	3,635,962	0.2	9	222,408	20.5	2,155,961	0.2	
5 and younger	770	0.2	7,369	0.4	44	146,474	45.4	1,349,940	0.2	6	58,652	18.2	578,022	0.2	
6-14	3,072	1.0	31,769	0.6	55	93,422	31.2	986,312	0.1	7	50,032	16.7	530,799	0.1	2
15-20	2,284	1.7	22,764	0.6	63	41,794	30.8	435,480	0.2	11	21,064	15.5	215,975	0.1	2
21-44	12,407	5.7	108,308	0.5	53	51,314	23.6	468,998	0.2	13	52,341	24.0	448,792	0.2	
45-64	7,447	7.5	70,770	0.5	49	35,570	35.6	350,987	0.2	15	37,694	37.8	354,185	0.3	18
65-74	361	5.8	3,826	0.5	46	2,561	41.2	28,240	0.2	16	1,836	29.5	19,496	0.3	23
75-84	156	4.3	1,682	0.5	31	1,128	31.0	12,720	0.2	15	663	18.2	7,288	0.3	26
85 and older	47	2.3	534	0.4	34	290	14.4	3,285	0.2	16	126	6.3	1,404	0.3	24
Unknown	8	0.0	26	0.5	32	2,630	2.8	18,263	0.2	5	469	0.5	2,832	0.2	2

Table ND7C Nondual Beneficiaries

- a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND7C Nondual Beneficiaries

TABLE ND.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c} NONDUAL BENEFICIARIES, NEW YORK, 2004

		ANTII	DIABETIC				ANTIHYP	ERLIPIDEMI	0			
Beneficiary Characteristics	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month		Number of Benefit Months
All	198,057	6.4 %	2,058,665	0.6	\$44	163,089	5.2 %	1,733,715	0.5	\$51	3,109,338	26,041,145
Female	123,818	7.2	1,309,037	0.6	44	98,493	5.7	1,064,452	0.5	51	1,720,786	14,672,100
Disabled	63,195	29.5	722,567	0.7	47	52,163	24.3	599,492	0.6	54	214,400	2,354,111
5 and younger	36	0.4	393	0.5	71	19	0.2	200	0.3	21	8,057	79,075
6-14	263	1.4	2,983	0.7	62	32	0.2	359	0.4	28	18,140	197,941
15-20	456	3.2	5,180	0.6	51	83	0.6	951	0.4	30	14,230	154,094
21-44	9,156	14.8	104,059	0.6	41	6,078	9.8	69,634	0.5	46	62,033	684,473
45-64	52,008	48.0	595,549	0.7	48	44,840	41.4	515,568	0.6	55	108,344	1,200,788
65-74	1,138	40.0	12,900	0.7	49	1,002	35.2	11,539	0.6	58	2,844	30,467
75-84	128	22.7	1,390	0.6	42	103	18.3	1,176	0.6	57	564	5,467
	10	5.3	113	0.4	31	6	3.2	65	0.6	56	188	1,806
85 and older Other Eligibles	60,620	4.0	586,456	0.6	39	46,330	3.1	464,960	0.5	47	1,506,386	12,317,989
_	153	0.0	1,251	0.6	53	50	0.0	476	0.2	5	308,148	2,448,108
5 and younger	1,234	0.4	12,564	0.6	58	101	0.0	1,109	0.3	31	295,451	2,614,073
6-14	1,674	8.0	16,456	0.5	41	234	0.1	2,361	0.3	25	204,329	1,683,801
15-20	21,100	3.9	196,919	0.5	35	10,617	2.0	104,780	0.4	37	544,066	4,209,394
21-44	31,212	23.8	303,447	0.6	42	29,996	22.9	298,545	0.5	49	131,165	1,142,944
45-64	3,490	34.2	36,662	0.6	35	3,516	34.4	37,844	0.5	51	10,217	96,044
65-74	1,491	22.8	16,242	0.6	32	1,563	23.9	17,123	0.5	51	6,546	62,000
75-84	266	4.1	2,915	0.5	28	253	3.9	2,722	0.5	53	6,464	61,625
85 and older	74.000	<i>-</i> -	740 500	0.0	45	04.500	5 0	000 044	0.0	50	4 005 007	40,000,404
Male	74,232	5.7	749,562	0.6	45	64,593	5.0	669,244	0.6	52	1,295,667	10,929,124
Disabled	33,357	16.0	374,168	0.7	47	30,707	14.7	347,998	0.6	55	208,214	2,238,434
5 and younger	37	0.3	442	0.6	71	15	0.1	163	0.2	8	12,924	127,981
6-14	310	0.8	3,498	0.7	65	37	0.1	433	0.4	25	36,870	402,887
15-20	345	1.5	3,901	0.6	67	109	0.5	1,232	0.5	36	23,284	252,628
21-44	5,787	9.8	64,936	0.6	43	5,985	10.1	68,263	0.5	46	59,098	641,055
45-64	26,402	35.8	295,919	0.7	47	24,070	32.6	272,240	0.6	57	73,845	791,179
65-74	432	23.7	4,994	0.6	44	450	24.7	5,207	0.6	55	1,824	18,991
75-84	38	12.2	410	0.5	28	39	12.5	438	0.6	55	312	3,181
	6	10.5	68	0.5	28	2	3.5	22	8.0	91	57	532
85 and older Other Eligibles	40,875	3.8	375,394	0.6	43	33,886	3.1	321,246	0.5	48	1,087,453	8,690,690
5 and younger	167	0.1	1,507	0.6	66	53	0.0	525	0.2	9	322,894	2,565,875
6-14	1,000	0.3	9,956	0.6	59	127	0.0	1,359	0.3	23	299,346	2,638,885
15-20	980	0.7	10,014	0.6	58	241	0.2	2,440	0.3	27	135,719	1,124,969
15-20 21-44	12,029	5.5	104,393	0.6	41	10,019	4.6	91,434	0.4	41	217,822	1,466,215
45-64	24,314	24.4	224,779	0.6	43	20,887	20.9	198,116	0.5	52	99,802	785,897
	1,710	27.5	17,375	0.6	36	1,765	28.4	18,672	0.5	52	6,221	56,407
65-74	574	15.8	6,266	0.6	36	686	18.8	7,526	0.5	52	3,640	33,905
75-84	101	5.0	1,104	0.6	29	108	5.4	1,174	0.5	51	2,009	18,537
85 and older Unknown	10	0.0	80	0.3	13	3	0.0	19	0.3	13	92,885	439,921

Table ND7D Nondual Beneficiaries

- a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE ND.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC^{a, b} NONDUAL BENEFICIARIES, NEW YORK, 2004

5 (* :		N 1 (D D C)	NI I CAUNC NI '	Benefit Months Among All-
Beneficiary	Dy C par Panafit Manth	Number of Rx per Benefit	Number of All-Year Nursing	Year Nursing Facility
Characteristics	Rx \$ per Benefit Month	Month	Facility Residents	Residents
All	\$337	2.0	8,669	95,700
Age				
0-64	393	2.3	6,646	74,507
65-74	206	1.6	678	7,518
75-84	141	1.3	665	7,040
85 and older	67	0.5	680	6,635
Unknown	0	0.0	0	0
Gender				
Female	291	2.0	4,192	46,174
Male	380	2.1	4,477	49,526
Unknown	0	0.0	0	0
Race				
White	260	1.7	3,390	36,331
African American	418	2.4	1,990	21,990
Other/unknown	365	2.2	3,289	37,379
Basis of Eligibility ^c				
Aged	123	1.1	1,628	16,770
Disabled	371	2.2	6,878	77,380
Adults	1,038	4.4	130	1,219
Children	728	2.3	33	331
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2004 file for New York, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2004 Medicaid enrollment. A total of 9,088 beneficiaries who were in nursing facilities for part of their enrollment and their 94,006 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

TABLE ND.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORY NONDUAL BENEFICIARIES, NEW YORK, 2004

		per of Ro	ng Use			er Bene Among		th		\$ per	Rx			_		Users	
Therapeutic Category	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total	Patented Brand- Name	Off-Patent Brand- Name	Generic	Total Number of Rx	Total Rx \$	F Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	2.5	2.3	0.1	0.1	###	\$653	\$16	\$6	\$266	\$279	\$223	\$49	39,992	\$10,649,076	1,373	15.8 %	15,782
Biologicals	0.4	0.3	0.0	0.1	607	462	3	142	1684	1,562	1,871	####	428	720,731	103	1.2	1,187
Antineoplastic Agents	0.5	0.1	0.0	0.5	72	26	0	46	133	446	0	95	344	45,590	55	0.6	632
Endocrine/Metabolic Drugs	1.1	0.4	0.1	0.5	77	54	5	18	73	121	49	36	8,402	616,779	679	7.8	7,972
Cardiovascular Agents	1.8	0.9	0.1	0.9	90	67	3	20	49	74	45	23	21,521	1,053,535	1,000	11.5	11,667
Respiratory Agents	0.8	0.5	0.0	0.3	48	41	0	7	63	89	38	22	4,929	308,340	548	6.3	6,383
Gastrointestinal Agents	0.7	0.3	0.0	0.3	70	52	2	15	98	154	78	44	5,958	582,543	716	8.3	8,337
Genitourinary Agents	0.5	0.4	0.0	0.1	39	33	2	4	71	83	82	34	1,983	141,465	311	3.6	3,643
CNS Drugs	1.5	1.2	0.0	0.3	273	251	4	18	178	210	122	60	62,846	11,208,495	3,566	41.1	41,059
Stimulants/Anti-obesity/Anorexia	0.4	0.4	0.0	0.0	74	73	0	0	199	202	30	17	112	22,290	26	0.3	303
Miscellaneous Psychological/																	
Neurological Agents	0.7	0.6	0.0		347	344	0	2	524	533	102	154	1,774	929,210	229	2.6	2,681
Analgesics and Anesthetics	0.7	0.5	0.0		74	62	6	6	107	133	529	29	8,739	938,470	1,076	12.4	12,621
Neuromuscular Agents	1.1	0.6	0.1	0.5	96	68	11	17	84	123	115	35	22,400	1,877,627	1,686	19.4	19,624
Nutritional Products	0.6	0.0	0.0	0.5	13	1	0	11	22	58	21	21	1,019	22,638	154	1.8	1,786
Hematological Agents	8.0	0.6	0.0	0.2	330	325	2	3	392	556	46	13	6,623	2,594,081	700	8.1	7,859
Topical Products	0.6	0.3	0.0	0.3	38	25	3	10	61	97	60	31	6,461	391,215	884	10.2	10,322
Miscellaneous Products	0.4	0.1	0.1	0.2	85	36	36	12	235	275	520	77	140	32,872	33	0.4	388
Unknown Therapeutic Category	0.6	0.0	0.0	0.0	43	0	0	0	73	0	0	0	1,612	117,303	230	2.7	2,698
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	195,283	32,252,260	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for New York, released by CMS in 01/2008. This table was produced on 03/25/2008.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 9,088 beneficiaries who were in nursing facilities for part of their enrollment and their 94,006 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In New York, 0.6 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND9 Nondual Beneficiaries

TABLE ND.10

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP-10 DRUG GROUP^{a, b, c, d}

NONDUAL BENEFICIARIES, NEW YORK, 2004

			Users		Among Users			
		Number of	As a Percentage of All-Year	Number of	Number of Dyner		Dy f nor Donofit	
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Users	Nursing Facility Residents	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month	
ANTIPSYCHOTICS	\$10,581,162	3,856	44.5 %	44,452	1.2	\$204	\$238	
ANTIVIRAL	10,344,875	2,236	25.8	25,323	1.4	283	409	
HEMATOPOIETIC AGENTS	2,418,524	665	7.7	7,446	0.7	454	325	
ANTICONVULSANT	1,776,726	1,652	19.1	19,289	1.0	93	92	
MISC PSYCHOTHERAPEUTIC AND								
NEUROLOGICAL	933,695	297	3.4	3,495	0.5	509	267	
PASSIVE IMMUNIZING AGENTS	719,417	57	0.7	638	0.6	1903	1,128	
MIGRAINE PRODUCTS	448,809	350	4.0	4,141	0.9	124	108	
ANTIDIABETIC	449,458	763	8.8	8,986	0.7	68	50	
ANTIHYPERLIPIDEMIC	448,693	612	7.1	7,177	0.7	93	63	
ULCER DRUGS	440,879	655	7.6	7,641	0.6	102	58	
Total	28,562,238	11,143		128,588	n.a.	n.a.	n.a.	

Source: Data for this table are from the MAX 2004 file for New York, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 9,088 beneficiaries who were in nursing facilities for part of their enrollment and their 94,006 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

NONDUAL BENEFICIARIES, NEW YORK, 2003

	All Top 10 Dr	ug Groups		ANTIPS	SYCHOTICS				AN ⁻	TIVIRAL		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	134,628	\$28,562,238	3,856	44.5 %	44,452	1.2	\$238	2,236	25.8 %	25,323	1.4	\$409
Female	58,332	11,342,880	1,825	43.5	21,055	1.1	218	665	15.9	7,552	1.4	365
Disabled	51,838	10,086,077	1,484	48.6	17,314	1.2	236	606	19.8	6,904	1.5	368
Disabicu	49,596	9.701.649	1,386	48.9	16.163	1.2	236	601	21.2	6.844	1.5	368
64 or younger	2,151	356,802	96	50.0	1,127	1.2	222	5	2.6	60	0.9	408
65-74	90	27,489	2	9.1		1.6	703	0	0.0	0	0.0	0
75-84	1	137	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	6.494	1.256.803	341	30.0	3.741	0.8	136	59	5.2	648	0.8	326
Other Eligibles	844	417,193	9	18.8	92	1.0	223	54	112.5	588	0.8	353
64 or younger	1,783	273,233	78	46.4	901	0.9	195	1	0.6	12	0.1	14
65-74	2,519	344.361	121	30.3	1.344	0.8	138	4	1.0	48	0.1	67
75-84	1,348	222,016	133	25.6	1,404	0.7	91	0	0.0	0	0.0	0
85 and older	,	,			•							
Male	76,296	17,219,358	2,031	45.4	23,397	1.2	256	1,571	35.1	17,771	1.5	427
Disabled	69,382	15,645,605	1,796	47.0	20,820	1.3	264	1,405	36.8	15,944	1.5	428
64 or younger	67,293	15,237,926	1,709	46.9	19,823	1.3	266	1,388	38.1	15,788	1.5	429
65-74	2,019	381,336	81	50.0	931	1.1	228	17	10.5	156	1.2	418
75-84	44	11,322	5	45.5	54	0.8	208	0	0.0	0	0.0	0
85 and older	26	15,021	1	33.3	12	1.5	222	0	0.0	0	0.0	0
Other Eligibles	6,914	1,573,753	235	35.9	2,577	0.9	191	166	25.3	1,827	1.2	416
64 or your gor	2,815	893,317	23	20.0	247	8.0	211	165	143.5	1,815	1.2	419
64 or younger 65-74	1,591	261,829	75	48.1	850	1.0	203	0	0.0	0	0.0	0
75-84	1,701	297,183	87	37.5	972	0.9	195	1	0.4	12	0.1	14
75-84 85 and older	807	121,424	50	32.9	508	0.9	155	0	0.0	0	0.0	0
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 9,088 beneficiaries who were in nursing facilities for part of their enrollment and their 94,006 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, NEW YORK, 2003

	-	НЕМАТОРО	DIETIC AGEN	NTS		-	ANTICO	ONVULSANT			MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL				
Beneficiary	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean
Characteristics	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx \$
All	665	7.7 %	7,446	0.7	\$325	1,652	19.1 %	19,289	1.0	\$92	297	3.4 %	3,495	0.5	\$267
Female	331	7.9	3,725	0.7	264	836	19.9	9,745	1.0	90	178	4.2	2,105	0.6	329
Disabled	264	8.6	2,999	0.7	284	752	24.6	8,792	1.0	94	120	3.9	1,422	0.6	460
r	251	8.8	2,852	0.7	292	722	25.4	8,453	1.0	94	113	4.0	1,338	0.6	485
64 or younge	10	5.2	111	0.5	87	29	15.1	338	0.9	92	5	2.6	60	0.5	66
65-74	3	13.6	36	0.6	208	1	4.5	1	1.0	113	1	4.5	12	8.0	105
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	20.0	12	0.1	11
85 and older Other Eligibles	67	5.9	726	0.5	180	84	7.4	953	0.8	53	58	5.1	683	0.4	56
r	4	8.3	46	0.5	4	11	22.9	116	0.6	63	5	10.4	57	0.3	41
64 or younge	17	10.1	177	0.3	109	28	16.7	329	1.2	86	14	8.3	168	0.4	58
65-74	23	5.8	259	0.5	152	32	8.0	357	0.7	30	38	9.5	446	0.4	56
75-84	23	4.4	244	0.6	296	13	2.5	151	0.6	26	1	0.2	12	0.8	115
85 and older	224	7.5	2 724	0.7	200	040	40.0	0.544	4.0	0.4	440	0.7	4 200	0.5	474
Male	334	7.5	3,721	0.7	386	816	18.2	9,544	1.0	94	119	2.7	1,390	0.5	174
Disabled	282	7.4	3,139	0.8	431	742	19.4	8,710	1.0	98	76	2.0	883	0.5	244
64 or younge	276	7.6	3,083	0.8	423	711	19.5	8,340	1.0	99	73	2.0	856	0.5	249
65-74	5	3.1	49	1.3	770	29	17.9	348	1.0	76 7	3	1.9	27	0.5	78
75-84	0	0.0	0 7	0.0 0.9	0	1	9.1 33.3	10	0.2	7	0	0.0 0.0	0	0.0	0
85 and older		33.3	-		1,749	•		12	0.2	9	0		0	0.0	0
85 and older Other Eligibles	52	7.9	582	0.4	143	74	11.3	834	0.8	59	43	6.6	507	0.4	52
r 64 or younge	14	12.2	151	0.4	71	13	11.3	156	0.7	65	9	7.8	105	0.1	15
65-74	11	7.1	130	0.4	147	21	13.5	232	0.9	79	8	5.1	96	0.3	44
75-84	18	7.8	206	0.4	181	29	12.5	329	8.0	45	18	7.8	210	0.5	65
85 and older	9	5.9	95	0.6	169	11	7.2	117	8.0	48	8	5.3	96	0.6	70
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2003 file for New York, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit: \$ = Medicaid reimbursement.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 9,088 beneficiaries who were in nursing facilities for part of their enrollment and their 94,006 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} NONDUAL BENEFICIARIES, NEW YORK, 2003

	PASSIVE IMMUNIZING AGENTS					MIGRAINE PRODUCTS					ANTIDIABETIC				
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Users	Mean Number of Rx	Mean Rx \$
All	57	0.7 %	638	0.6	\$1,128	350	4.0 %	4,141	0.9	\$108	763	8.8 %	8,986	0.7	\$50
Female	30	0.7	344	0.6	1,337	160	3.8	1,893	8.0	96	454	10.8	5,368	8.0	52
Disabled	26	0.9	297	0.6	983	153	5.0	1,812	0.8	96	372	12.2	4,414	0.8	54
r 64 or younge	26	0.9	297	0.6	983	150	5.3	1,776	8.0	97	355	12.5	4,210	0.8	54
65-74	0	0.0	0	0.0	0	3	1.6	36	0.5	60	15	7.8	180	0.7	57
75-84	0	0.0 0.0	0	0.0	0	0	0.0 0.0	0	0.0	0 0	2	9.1 0.0	24 0	0.5 0.0	27 0
85 and older Other Eligibles	4	0.0	0 47	1.1	3,576	7	0.6	81	0.0	91	82	7.2	954	0.6	44
Other Eligibles	4	8.3	47	1.1	3,576	1	2.1	9	1.2	191	7	14.6	54	0.6	59
64 or younge '	0	0.0	0	0.0	0,570	3	1.8	36	0.8	62	25	14.9	300	0.7	50
65-74	0	0.0	0	0.0	0	3	0.8	36	1.0	96	44	11.0	528	0.6	42
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	6	1.2	72	0.6	20
85 and older	07	0.0	004	0.5	000	400	4.0	0.040		440	000	0.0	0.040		4-7
Male	27	0.6 0.6	294 258	0.5 0.6	882 877	190 177	4.2 4.6	2,248 2,092	0.9 0.9	119 120	309 258	6.9 6.8	3,618 3,021	0.7 0.7	47 45
Disabled	24 24	0.6	256 258	0.6	877	168	4.6 4.6	1,984	0.9	120	239	6.6	2,811	0.7	45 45
64 or younge	0	0.7	0	0.0	0	9	5.6	1,904	1.3	146	19	11.7	210	0.7	51
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	3	0.5	36	0.4	922	13	2.0	156	0.9	106	51	7.8	597	0.7	57
r	3	2.6	36	0.4	922	2	1.7	24	0.7	110	9	7.8	93	0.8	57
64 or younge	0	0.0	0	0.0	0	7	4.5	84	1.1	146	26	16.7	312	0.7	51
65-74	0	0.0	0	0.0	0	4	1.7	48	0.5	33	13	5.6	156	0.6	70
75-84 85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	2.0	36	0.8	56
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2003 file for New York, released by CMS in 01/2008. This table was produced on 03/25/2008.

- a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 9,088 beneficiaries who were in nursing facilities for part of their enrollment and their 94,006 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Table ND10C Nondual Beneficiaries

TABLE ND.10D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{6, b, c, d} NONDUAL BENEFICIARIES, NEW YORK, 2003

		ANTIHYP	ERLIPIDEMI	С			ULCE	R DRUGS				
		Users as % of All-Year Nursing	Number of Benefit Months	Mean			Users as % of All-Year Nursing	Number of Benefit Months	Mean		All-Year Nursing \	Benefit Months Among All- Year Nursing
Beneficiary	Number of	Facility	Among	Number	Mean	Number of	Facility	Among	Number	Mean	Facility	Facility
Characteristics	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx\$	Residents	Residents
All	612	7.1 %	7,177	0.7	\$63	655	7.6 %	7,641	0.6	\$58	8,669	95,700
Female	361	8.6	4,257	0.7	65	396	9.4	4,654	0.6	56	4,192	46,174
Disabled	274	9.0	3,255	0.7	67	327	10.7	3,855	0.6	56	3,056	34,587
0.4	260	9.2	3,087	0.7	67	308	10.9	3,627	0.6	55	2,837	32,111
64 or younger	13	6.8	156	0.6	62	19	9.9	228	0.7	70	192	2,202
65-74	1	4.5	12	0.9	93	0	0.0	0	0.0	0	22	221
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	5	53
85 and older Other Eligibles	87	7.7	1,002	0.6	58	69	6.1	799	0.5	53	1,136	11,587
_	4	8.3	27	1.2	118	7	14.6	70	0.3	42	48	449
64 or younger	26	15.5	312	0.5	49	14	8.3	168	0.4	46	168	1,832
65-74	47	11.8	543	0.6	58	37	9.3	429	0.5	57	400	4,211
75-84	10	1.9	120	0.6	64	11	2.1	132	0.4	56	520	5,095
85 and older	054		0.000		00	050	5.0	0.007	0.0	0.4	4 477	40.500
Male	251	5.6	2,920	0.7	60	259	5.8	2,987	0.6	61	4,477	49,526
Disabled	191	5.0	2,236	0.7	60	207	5.4	2,392	0.6	60	3,822	42,793
64 or younger	179	4.9	2,101	0.7	62	196	5.4	2,260	0.6	61	3,646	40,846
65-74	12	7.4	135	0.5	38	11	6.8	132	0.6	50	162	1,806
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	11	110
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	31
85 and older Other Eligibles	60	9.2	684	0.6	58	52	7.9	595	0.5	65	655	6,733
64 or younger	18	15.7	186	0.7	58	14	12.2	153	0.4	44	115	1,101
65-74	12	7.7	144	0.6	60	13	8.3	150	0.5	74	156	1,678
75-84	23	9.9	270	0.6	56	18	7.8	208	0.5	67	232	2,498
85 and older	7	4.6	84	0.7	61	7	4.6	84	0.7	84	152	1,456
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2003 file for New York, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2003. A total of 9,088 beneficiaries who were in nursing facilities for part of their enrollment and their 94,006 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2003. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2003 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE ND.11

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}

NEW YORK, 2003

	Number of	Percentage of							
	Beneficiaries with	Beneficiaries with at	Number of Part	Total Number Pa	art D Excluded			Part D Excluded Rx	
Beneficiary	at Least One Part	Least One Part D	D Excluded Rx	Part D	Rx \$ per	Total Part D	\$ per Part D \$	as a Percentage of	Total Number of
Characteristics	D Excluded Rx	Excluded Rx	per Beneficiary	Excluded Rx	Beneficiary	Excluded Rx \$	Excluded Rx	All Nondual Rx \$	Beneficiaries
All	1,237,064	39.8 %	1.8	5,708,708	\$19	\$59,596,510	\$10	2.3 %	3,109,338
Age									
5 and younger	354,468	54.4	2.0	1,280,103	12	7,649,455	6	5.6	652,028
6-14	252,249	38.8	1.1	706,749	10	6,807,590	10	2.9	649,807
15-20	94,669	25.1	0.7	251,802	9	3,436,380	14	2.6	377,562
21-44	284,740	32.2	1.4	1,253,499	20	18,095,918	14	2.1	883,019
45-64	231,884	56.1	5.0	2,068,592	55	22,775,986	11	1.9	413,156
65-74	10,329	48.9	4.4	91,873	25	537,785	6	1.5	21,106
75-84	3,895	35.2	3.2	35,741	17	187,321	5	1.4	11,062
85 and older	987	11.3	1.2	10,277	6	53,812	5	1.5	8,718
Unknown	3,843	4.1	0.1	10,072	1	52,263	5	6.1	92,880
Basis of Eligibility ^c									
Aged	12,802	36.4	3.2	111,141	17	612,591	6	1.5	35,195
Disabled	228,373	54.0	5.1	2,140,585	72	30,596,241	14	2.1	422,618
Adults	334,892	33.9	1.4	1,418,917	15	14,622,836	10	1.9	987,343
Children	660,858	39.7	1.2	2,037,596	8	13,758,540	7	4.0	1,663,459
Unknown	139	19.2	0.6	469	9	6,302	13	0.6	723
Gender									
Female	729,054	41.9	2.0	3,512,831	22	37,435,796	11	2.6	1,739,646
Male	504,249	38.3	1.7	2,185,942	17	22,109,014	10	1.9	1,315,367
Unknown	3,761	6.9	0.2	9,935	1	51,700	5	6.2	54,325
Race									
White	308,328	31.8	1.5	1,444,845	20	19,564,715	14	2.4	970,791
African American	295,491	38.1	1.6	1,239,122	16	12,433,487	10	1.8	775,629
Other/unknown	633,245	46.5	2.2	3,024,741	20	27,598,308	9	2.5	1,362,918
Use of Nursing									
Facilities ^d									
Entire year	1,216	14.0	2.3	19,700	39	340,625	17	1.1	8,669
Part year	5,318	58.5	6.0	54,808	63	574,653	10	1.1	9,088
None	1,230,530	39.8	1.8	5,634,200	19	58,681,232	10	2.3	3,091,581
Maintenance									
Assistance Status									
Cash	652,577	46.6	2.5	3,440,247	28	38,638,847	11	2.3	1,399,365
Medically needy	192,151	36.3	1.4	758,523	15	7,681,403	10	2.9	529,163
Poverty related	199,320	37.0	1.1	602,678	8	4,258,165	7	4.1	538,881
Other/unknown	193,016	30.1	1.4	907,260	14	9,018,095	10	1.6	641,929

Table ND11 Nondual Beneficiaries

- a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}

NEW YORK, 2003

Beneficiary	Number Rx per	Rx \$ per		Barbiturate \$ per Ber	nzodiazepine \$ per	Number of
Characteristics	Benefit Month	Benefit Month	\$ per Rx	Benefit Month	Benefit Month	Benefit Months
All	0.2	\$2	\$10	\$0	\$0	26,041,145
Age						
5 and younger	0.2	1	6	0	0	5,221,063
6-14	0.1	1	10	0	0	5,853,786
15-20	0.1	1	14	0	0	3,215,492
21-44	0.2	3	14	0	1	7,001,137
45-64	0.5	6	11	0	2	3,920,808
65-74	0.5	3	6	0	0	201,909
75-84	0.3	2	5	0	0	104,553
85 and older	0.1	1	5	0	0	82,500
Unknown	0.0	0	5	0	0	439,897
Basis of Eligibility ^c						
Aged	0.3	2	6	0	0	328,669
Disabled	0.5	7	14	0	2	4,592,552
Adults	0.2	2	10	0	0	7,578,435
Children	0.2	1	7	0	0	13,536,447
Unknown	0.1	1	13	0	1	5,042
Gender						
Female	0.2	3	11	0	0	14,735,249
Male	0.2	2	10	0	0	10,994,298
Unknown	0.0	0	5	0	0	311,598
Race						
White	0.2	2	14	0	1	8,235,692
African American	0.2	2	10	0	0	6,342,160
Other/unknown	0.3	2	9	0	0	11,463,293
Use of Nursing						
Facilities ^d						
Entire year	0.2	4	17	0	1	95,700
Part year	0.6	6	10	0	1	94,006
None	0.2	2	10	0	0	25,851,439
Maintenance						
Assistance Status						
Cash	0.3	3	11	0	1	12,819,455
Medically needy	0.2	2	10	0	0	4,033,506
Poverty related	0.1	1	7	0	0	4,190,198
Other/unknown	0.2	2	10	0	0	4,997,986

Table ND12 Nondual Beneficiaries

- a. Table ND.12 includes the beneficaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.13 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS^{a,b,c} NEW YORK, 2003

				Rx \$ as a Percentage of All Part D			Number Rx as a Percentage of All Part D
Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Excluded Rx \$	Total Number Rx.	\$ per Rx	Excluded Rx
All	1,368,516	\$44	\$59,596,510	100.0 %	5,708,708	\$10	100.0 %
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	71	206	14,651	0.0	171	86	0.0
Drugs for cosmetic purposes	0	0	0	0.0	0	0	0.0
Cough and cold medications	36,487	75	2,740,797	4.6	61,724	44	1.1
Vitamins and minerals	92,320	51	4,707,706	7.9	238,700	20	4.2
Non-prescription drugs	1,142,389	24	27,711,060	46.5	4,918,160	6	86.2
Barbiturates	5,591	66	370,529	0.6	46,016	8	0.8
Benzodiazepines	68,253	173	11,782,008	19.8	371,718	32	6.5
Other Part D Excl Rx Drugs	23,405	524	12,269,759	20.6	72,219	170	1.3

Source: Data for this table are from the MAX 2003 file for New York, released by CMS in 01/2008. This table was produced on 03/25/2008.

- a. Table ND.13 includes the beneficaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2003. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2003. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.
- b. Includes OTC drugs as well as prescription drugs.
- c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

APPENDIX TABLE A.1
CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
NONDUAL BENEFICIARIES, NEW YORK, 2003

Beneficiary			Number of Be	eneficiaries			Number of Benefit Months					
Characteristics	All	Aged	Disabled	Adults	Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	3,734,091	38,320	432,531	1,179,223	2,083,294	723	36,384,449	366,998	4,836,481	10,905,143	20,270,741	5,086
Age												
5 and younger	753,876	8	21,781	0	732,087	0	7,354,403	67	229,508	0	7,124,828	0
6-14	850,047	2	58,127	0	791,918	0	8,811,880	24	654,926	0	8,156,930	0
15-20	495,137	0	39,165	0	455,927	45	4,895,241	0	434,310	0	4,460,655	276
21-44	1,033,280	0	123,261	902,123	7,519	377	9,636,085	0	1,385,693	8,212,250	35,795	2,347
45-64	461,550	0	184,329	276,915	6	300	4,764,620	0	2,070,156	2,691,954	59	2,451
65-74	23,731	18,811	4,734	185	0	1	233,442	181,771	50,720	939	0	12
75-84	11,618	10,735	883	0	0	0	111,607	102,836	8,771	0	0	0
85 and older	8,800	8,553	247	0	0	0	83,979	81,595	2,384	0	0	0
Unknown	96,052	211	4	0	95,837	0	493,192	705	13	0	492,474	0
Gender												
Female	2,061,045	25,057	218,434	785,781	1,031,050	723	20,255,221	242,039	2,468,339	7,424,962	10,114,795	5,086
Male	1,615,754	13,232	214,095	393,442	994,985	0	15,778,577	124,775	2,368,131	3,480,181	9,805,490	0
Unknown	57,292	31	2	0	57,259	0	350,651	184	11	0	350,456	0
Race												
White	1,121,295	10,537	133,829	371,904	604,474	551	10,891,449	98,729	1,490,960	3,414,965	5,882,892	3,903
African American	959,317	6,409	106,154	339,908	506,776	70	9,324,808	59,963	1,186,053	3,108,976	4,969,350	466
Other/unknown	1,653,479	21,374	192,548	467,411	972,044	102	16,168,192	208,306	2,159,468	4,381,202	9,418,499	717
Use of Nursing Facilities ^c												
Entire year	8,671	1,628	6,878	132	33	0	95,882	16,770	77,509	1,272	331	0
Part year	9,093	917	7,194	886	96	0	97,088	9,041	77,964	9,081	1,002	0
None	3,716,327	35,775	418,459	1,178,205	2,083,165	723	36,191,479	341,187	4,681,008	10,894,790	20,269,408	5,086
Maintenance Assistance Status												
Cash	1,654,854	9,250	374,448	330,052	941,104	0	16,966,705	88,965	4,262,611	3,183,714	9,431,415	0
Medically needy	637,238	23,997	55,491	199,447	358,303	0	5,828,559	228,896	548,396	1,817,032	3,234,235	0
Poverty related	677,421	6	1	1,585	675,106	723	6,558,100	44	12	9,478	6,543,480	5,086
Other/unknown	764,578	5,067	2,591	648,139	108,781	0	7,031,085	49,093	25,462	5,894,919	1,061,611	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	1,219,934	30,789	335,600	336,859	515,973	713	10,617,145	288,989	3,717,832	2,554,021	4,051,313	4,990
FFS part year, with Rx claims	460,461	969	19,730	189,824	249,930	8	4,616,334	10,361	219,577	1,843,023	2,543,297	76
FFS part year, no Rx claims	309,687	582	3,276	104,369	201,458	2	2,665,481	5,630	33,008	878,400	1,748,423	20
MC all year, with Rx claims	1,119,256	2,855	64,012	356,291	696,098	0	12,699,755	32,900	758,513	3,982,073	7,926,269	0
MC all year, no Rx claims	624,655	3,125	9,913	191,837	419,780	0	5,785,107	29,118	107,551	1,647,376	4,001,062	0

- a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a NONDUAL BENEFICIARIES, NEW YORK, 2003

	Beneficiarie Benefit Months in Ce		Included in Cell K	of Table 1	Excluded from Cell	K of Table 1	
	Number of Nu	umber of Benefit	Number of Nu	ımber of Benefit	Number of Number of Benefit		
All	Beneficiaries	Months 26 394 440	Beneficiaries	Months 26 044 445	Beneficiaries	Months	
	3,734,091	36,384,449	3,109,338	26,041,145	0	10,343,304	
Fee-for-service (FFS) all year	1,219,934	10,617,145	1,219,934	10,613,900	0	3,245	
FFS part year, with Rx claims	460,461	4,616,334	460,461	1,704,326	0	2,912,008	
FFS part year, with no Rx claims	309,687	2,665,481	309,687	1,023,940	0	1,641,541	
Managed care (MC) all year, with Rx claims	1,119,256	12,699,755	1,119,256	12,698,979	0	776	
MC all year, with no Rx claims	624,655	5,785,107	0	0	0	5,785,107	

Source: Data for this table are from the MAX 2003 file for New York, released by CMS in 01/2008. This table was produced on 03/25/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.